Verona Pharma plc: PDMR Dealing – Purchase by Chairman
LONDON, Nov. 18, 2019 (GLOBE NEWSWIRE) — Verona Pharma plc (AIM:VRP) (Nasdaq:VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces that Dr. David Ebsworth, Chairman of the Company, has notified the Company that he has purchased a further 25,000 ordinary shares of 5 pence each in the Company (“Ordinary Shares”) at a total purchase price of £11,750, at a price of 47 pence per Ordinary Share. This purchase brings the total purchases made by Dr. Ebsworth during 2019 to approximately £125,000.
Following the purchase, Dr. Ebsworth will have an interest in the Company of 395,387 Ordinary Shares, representing 0.38% of the Company’s issued share capital.Further information is provided below in accordance with the requirements of the EU Market Abuse Regulation.Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them
For further information, please contact:Mia Gardner (Corporate Broking)